We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-14.64%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.19B
AUM Growth
-$126M
Cap. Flow
+$122M
Cap. Flow %
10.23%
Top 10 Hldgs %
29.08%
Holding
134
New
12
Increased
77
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.7M
2
WBA
Walgreens Boots Alliance
WBA
+$9.86M
3
ALKS icon
Alkermes
ALKS
+$7.68M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$7.42M
5
RDUS
Radius Health, Inc.
RDUS
+$7.3M

Top Sells

Rank Stock Value
1
IDXX icon
Idexx Laboratories
IDXX
+$9.3M
2
RLYP
RELYPSA INC COM
RLYP
+$7.14M
3
ABBV icon
AbbVie
ABBV
+$5.18M
4
DYAX
DYAX CORPORATION
DYAX
+$4.67M
5
TVTX icon
Travere Therapeutics
TVTX
+$2.33M

Sector Composition

Rank Sector Weight
1 Healthcare 77.87%
2 Financials 3.87%
3 Industrials 0.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RIGL icon
101
Rigel Pharmaceuticals
RIGL
$750M
$3.04M 0.26%
146,405
+36,405
+33% +$898K
CYTO
102
DELISTED
Altamira Therapeutics Ltd
CYTO
$2.87M 0.24%
+10
New +$3.56M
SCYX icon
103
SCYNEXIS
SCYX
$52M
$2.56M 0.21%
7,938
– –
SRPT icon
104
Sarepta Therapeutics
SRPT
$1.77B
$2.56M 0.21%
131,000
+23,500
+22% +$411K
CLVS
105
DELISTED
Clovis Oncology, Inc.
CLVS
$2.4M 0.2%
125,000
– –
ALDR
106
DELISTED
Alder Biopharmaceuticals
ALDR
$2.39M 0.2%
+97,500
New +$2.26M
DBVT
107
DBV Technologies
DBVT
$847M
$2.38M 0.2%
7,300
+4,800
+192% +$1.35M
BHC icon
108
Bausch Health
BHC
$2.34B
$2.25M 0.19%
85,500
+1,800
+2% +$133K
ISEE
109
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$2.18M 0.18%
+51,500
New +$2.62M
DMTX
110
DELISTED
Dimension Therapeutics, Inc
DMTX
$2.13M 0.18%
271,370
– –
EGLT
111
DELISTED
Egalet Corporation
EGLT
$2.06M 0.17%
300,000
– –
ALPN
112
DELISTED
Alpine Immune Sciences Inc
ALPN
$2.04M 0.17%
122,250
– –
ASMB icon
113
Assembly Biosciences
ASMB
$529M
$1.96M 0.16%
32,500
+1,583
+5% +$106K
TTPH
114
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$1.85M 0.16%
20,000
+10,000
+100% +$999K
ATYR
115
aTyr Pharma
ATYR
$50.1M
$1.71M 0.14%
30,964
+1,307
+4% +$99.4K
DARE icon
116
Dare Bioscience
DARE
$21M
$1.69M 0.14%
5,208
– –
ANTH
117
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.63M 0.14%
56,250
+8,750
+18% +$237K
INFI
118
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.42M 0.12%
270,000
+55,000
+26% +$337K
ICPT
119
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.28M 0.11%
10,000
-5,500
-35% -$649K
GBT
120
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.24M 0.1%
78,000
+7,500
+11% +$133K
OREX
121
DELISTED
Orexigen Therapeutics, Inc.
OREX
$930K 0.08%
165,300
+300
+0.2% +$3.9K
PBYI icon
122
Puma Biotechnology
PBYI
$454M
$925K 0.08%
31,500
+20,500
+186% +$926K
SPHS
123
DELISTED
Sophiris Bio, Inc.
SPHS
$905K 0.08%
628,563
– –
BLUE
124
DELISTED
bluebird bio
BLUE
$850K 0.07%
1,544
– –
PTLA
125
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$714K 0.06%
+35,000
New +$1.11M
2 3 4
5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, Rock Springs Capital Management held 134 positions worth $1.19B, down 9.6% from $1.32B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management deployed $122M of net new capital in Q1 2016, opening 12 new positions and adding to 77 existing holdings. Its largest new stake was Bristol-Myers Squibb: 170,000 shares worth $10.9M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 77% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $2.33M trimmed.

  • Rock Springs Capital Management's largest Q1 2016 buy was Bristol-Myers Squibb: 170,000 shares worth $10.9M.
  • Rock Springs Capital Management added most to ANACOR PHARMACEUTICALS INC COM in Q1 2016, an estimated $7.42M increase.
  • Rock Springs Capital Management's biggest Q1 2016 reduction was Travere Therapeutics, cutting an estimated $2.33M.
  • Rock Springs Capital Management fully exited Idexx Laboratories in Q1 2016, selling an estimated $9.3M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $1.19B portfolio in Q1 2016.
  • Rock Springs Capital Management opened 12 new positions and closed 6 in Q1 2016.
  • Rock Springs Capital Management's portfolio value fell 9.6% quarter-over-quarter to $1.19B.

Based on Rock Springs Capital Management's 13F filing for Q1 2016, filed 16 May 2016.